Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29101977 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14778860 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14778856 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14778858 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18842331 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20176685 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL22519690 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL26451273 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL26451311 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL26451173 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730883-B2 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | ABBVIE INC. (US) | 2020-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730883-B2 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | CNKSR1, JAK2, TNF | SMN1; SMN2 2229/4885NPC1 4449/4885RAB9A 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.